CL · Insider Trading
Colgate-Palmolive Company
Every open-market purchase and sale reported by CL officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-10-02 | Lorrie M Norrington | Director | A | +300 | +$26.23K |
| 2026-10-02 | John P Bilbrey | Director | A | +271 | +$23.69K |
| 2026-10-02 | Brian Newman | Director | A | +214 | +$18.71K |
| 2026-09-18 | Gregory Malcolm | EVP and Controller | A | +1,081 | — |
| 2026-09-18 | John Hazlin | Chief Growth Officer | A | +3,908 | — |
| 2026-09-18 | Sally Massey | Chief People Officer | A | +3,333 | — |
| 2026-09-18 | Panagiotis Tsourapas | COO, CD, EMEA, APac, Skin | A | +4,597 | — |
| 2026-09-18 | Stanley J Sutula III | Chief Financial Officer | A | +8,045 | — |
| 2026-09-18 | Noel R. Wallace | Chairman, President & CEO | A | +29,649 | — |
| 2026-09-18 | Betsy Fishbone | CLO and Secretary | A | +2,207 | — |
| 2026-09-18 | Shane Grant | COO, Americas | A | +7,355 | — |
| 2026-09-15 | Shane Grant | COO, Americas | F | −622 | −$53.99K |
| 2026-09-15 | Gregory Malcolm | EVP and Controller | F | −543 | −$47.13K |
| 2026-09-15 | Betsy Fishbone | CLO and Secretary | F | −1,207 | −$104.77K |
| 2026-09-15 | Sally Massey | Chief People Officer | F | −1,796 | −$155.89K |
| 2026-09-15 | John Hazlin | Chief Growth Officer | F | −1,587 | −$137.75K |
| 2026-09-15 | Stanley J Sutula III | Chief Financial Officer | F | −3,509 | −$304.58K |
| 2026-09-15 | Panagiotis Tsourapas | COO, CD, EMEA, APac, Skin | F | −2,224 | −$193.04K |
| 2026-09-15 | Noel R. Wallace | Chairman, President & CEO | F | −12,479 | −$1.08M |
| 2026-08-26 | Panagiotis Tsourapas | COO, CD, EMEA, APac, Skin | Sell | −10,000 | −$920.48K |
| 2026-08-07 | John T Cahill | Director | MIXED | — | −$90.95K |
| 2026-08-07 | John T Cahill | Director | MIXED | — | −$90.95K |
| 2026-08-06 | Noel R. Wallace | Chairman, President & CEO | MIXED | — | −$6.42M |
| 2026-08-06 | Noel R. Wallace | Chairman, President & CEO | MIXED | — | −$6.42M |
| 2026-07-02 | Lorrie M Norrington | Director | A | +293 | +$26.21K |
| 2026-07-02 | John P Bilbrey | Director | A | +265 | +$23.70K |
| 2026-07-02 | Brian Newman | Director | A | +209 | +$18.70K |
| 2026-06-17 | Shane Grant | COO, Americas | F | −23,347 | −$2.12M |
| 2026-05-18 | Gregory Malcolm | EVP and Controller | Sell | −2,300 | −$203.41K |
| 2026-05-13 | John P Bilbrey | Director | A | +2,075 | — |
| 2026-05-13 | Christopher S. Boerner | Director | A | +1,383 | — |
| 2026-05-13 | John T Cahill | Director | A | +2,075 | — |
| 2026-05-13 | Lisa Edwards | Director | A | +2,075 | — |
| 2026-05-13 | C Martin Harris | Director | A | +1,556 | — |
| 2026-05-13 | Lorrie M Norrington | Director | A | +2,075 | — |
| 2026-05-13 | Martina Hundmejean | Director | A | +2,075 | — |
| 2026-05-13 | Kimberly A Nelson | Director | A | +2,075 | — |
| 2026-05-13 | Brian Newman | Director | A | +2,075 | — |
| 2026-05-11 | Sally Massey | Chief People Officer | Sell | −8,599 | −$751.63K |
| 2026-04-03 | John P Bilbrey | Director | A | +266 | +$23.69K |
| 2026-04-03 | Brian Newman | Director | A | +210 | +$18.70K |
| 2026-04-03 | Lorrie M Norrington | Director | A | +294 | +$26.18K |
| 2026-02-25 | Noel R. Wallace | Chairman, President & CEO | MIXED | +68,458 | −$6.63M |
| 2026-02-25 | Panagiotis Tsourapas | COO, Eur., APac, Afr Eur, Skin | MIXED | +12,661 | −$1.27M |
| 2026-02-25 | Stanley J Sutula III | Chief Financial Officer | MIXED | +18,932 | −$1.92M |
| 2026-02-25 | Sally Massey | Chief Human Resources Officer | MIXED | +8,599 | −$796.80K |
| 2026-02-25 | Gregory Malcolm | EVP and Controller | MIXED | +4,008 | −$219.45K |
| 2026-02-25 | Jennifer Daniels | CLO and Secretary | MIXED | +13,391 | −$1.20M |
| 2026-02-25 | John Hazlin | Chief Growth Officer | MIXED | +6,686 | −$593.96K |
| 2026-02-13 | Panagiotis Tsourapas | COO, Eur., APac, Afr Eur, Skin | MIXED | — | −$957.94K |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| Noel R. Wallace | Chairman, President & CEO | 380,035 | $35.77M |
| Jennifer Daniels | CLO and Secretary | 104,032 | $9.79M |
| Shane Grant | COO, Americas | 79,503 | $7.48M |
| Stanley J Sutula III | Chief Financial Officer | 79,360 | $7.47M |
| Panagiotis Tsourapas | COO, CD, EMEA, APac, Skin | 76,348 | $7.19M |
| John T Cahill | Director | 68,900 | $6.48M |
| Prabha Parameswaran | Vice Chair | 58,807 | $5.53M |
| John P Bilbrey | Director | 45,444 | $4.28M |
| Lorrie M Norrington | Director | 43,310 | $4.08M |
| John Hazlin | Chief Growth Officer | 32,534 | $3.06M |
| C Martin Harris | Director | 24,517 | $2.31M |
| Sally Massey | Chief People Officer | 23,596 | $2.22M |
| Gregory Malcolm | EVP and Controller | 22,812 | $2.15M |
| Lisa Edwards | Director | 18,182 | $1.71M |
| Martina Hundmejean | Director | 16,206 | $1.53M |
| Betsy Fishbone | CLO and Secretary | 16,100 | $1.52M |
| Kimberly A Nelson | Director | 11,849 | $1.12M |
| Brian Newman | Director | 8,094 | $761.73K |
| Steven A Cahillane | Director | 6,754 | $635.62K |
| Christopher S. Boerner | Director | 1,383 | $130.15K |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the CL quote page; the site-wide leaderboard is on the insider transactions hub.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.